Comparison of 3D conformal radiation therapy and intensity-modulated radiation therapy in patients with endometrial cancer: efficacy, safety and prognostic analysis

References

• Bray F, Ferlay J, Soerjomataram I, et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:1–31.
   Web of Science ®Google Scholar
• Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Radiother Oncol. 2015;117:559–581.
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet (London, England). 2000;355:1404–1411.
   PubMed Web of Science ®Google Scholar
• Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012;104:1625–1634.
   PubMedGoogle Scholar
• Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92:744–751.
   PubMed Web of Science ®Google Scholar
• Klopp AH, Jhingran A, Ramondetta L, et al. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009;115:6–11.
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, Nout RA, Lybeert MLM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:631–638.
   PubMed Web of Science ®Google Scholar
• Nout RA, Smit V, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816–823.
   PubMed Web of Science ®Google Scholar
• de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;2045:1–15.
   Google Scholar
• Jouglar E, Barillot I. Référentiels et techniques d’irradiation de haute précision: cancer de l’endomètre. Cancer/Radiotherapie 2014;18:495–500.
   Google Scholar
• Yang R, Xu S, Jiang W, et al. Dosimetric comparison of postoperative whole pelvic radiotherapy for endometrial cancer using three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and helical tomotherapy. Acta Oncol (Madr). 2010;49:230–236.
   PubMed Web of Science ®Google Scholar
• Lawrie TA, Green JT, Beresford M, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy. Cochrane Database Syst Rev. 2017;1:CD012529.
   Google Scholar
• Professionnelles Recommandations. ©Cancer de l’endomètre Collection, Recommandations & référentiels, INCa, Boulogne-Billancourt, November 2010.
   Google Scholar
• Grégoire V, Mackie TR. State of the art on dose prescription, reporting and recording in intensity-modulated radiation therapy (ICRU report No. 83). Cancer/Radiotherapie. 2011;15:555–559.
   Google Scholar
• Huguet F, Cojocariu OM, Levy P, et al. Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion. Int J Radiat Oncol Biol Phys. 2008;72:1508–1515.
   PubMed Web of Science ®Google Scholar
• Chassagne DP. La plésiocuriethérapie des cancers du vagin par moulage plastique avec l’iridium 192 (préparation non radioactive). J Radiol Electrol Med Nucl. 1966;47:89–93.
   Google Scholar
• Creutzberg CL, Van Putten WLJ, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89:201–209.
   PubMed Web of Science ®Google Scholar
• Sorbe BG, Horvath G, Andersson H, et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study - quality-of-life analysis. Int J Gynecol Cancer. 2012;22:1281–1288.
   PubMed Web of Science ®Google Scholar
• Beriwal S, Jain SK, Heron DE, et al. Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecol Oncol. 2006;102:195–199.
   PubMed Web of Science ®Google Scholar
• Shih KK, Milgrom SA, Abu-Rustum NR, et al. Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer. Gynecol Oncol. 2013;128:535–539.
   PubMed Web of Science ®Google Scholar
• Jhingran A, Winter K, Portelance L, et al. A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. Int J Radiat Oncol Biol Phys. 2012;84:e23–e28.
   PubMed Web of Science ®Google Scholar
• He S, Gill BS, Heron DE, et al. Long-term outcomes using adjuvant pelvic intensity modulated radiation therapy (IMRT) for endometrial carcinoma. Pract Radiat Oncol. 2017;7:19–25.
   PubMed Web of Science ®Google Scholar
• Barillot I, Tavernier E, Peignaux K, et al. Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: results of the phase II RTCMIENDOMETRE French multicentre trial. Radiother Oncol. 2014;111:138–143.
   PubMed Web of Science ®Google Scholar
• Bouchard M, Nadeau S, Gingras L, et al. Clinical outcome of adjuvant treatment of endometrial cancer using aperture-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;71:1343–1350.
   PubMed Web of Science ®Google Scholar
• Frost J, Webster K, Morrison J. Lymphadenectomy for the management of endometrial cancer (review) summary of findings for the main comparison. Cochrane Database Syst Rev. 2017;9:CD007585.
   Google Scholar
• Klee M, Machin D. Health-related quality of life of patients with endometrial cancer who are disease-free following external irradiation. Acta Oncol. 2001;40:816–824.
   PubMed Web of Science ®Google Scholar
• Klopp AH, Yeung AR, Deshmukh S, et al. A phase III randomized trial comparing patient-reported toxicity and quality of life (QOL) during pelvic intensity modulated radiation therapy as compared to conventional radiation therapy. Int J Radiat Oncol. 2016;96:S3.
   Web of Science ®Google Scholar
• de Boer SM, Powell ME, Mileshkin L, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:1114–1126.
   PubMed Web of Science ®Google Scholar
• Chen CC, Wang L, Lu CH, et al. Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy. J Formos Med Assoc. 2014;113:949–955.
   PubMed Web of Science ®Google Scholar
• Mundt AJ, Roeske JC, Lujan AE, et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 2001;82:456–463.
   PubMed Web of Science ®Google Scholar
• Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2003;56:1354–1360.
   PubMed Web of Science ®Google Scholar
• Cho LP, Cheng Z, McNutt TR, et al. Comparison of prospectively-collected genitourinary and gastrointestinal toxicities between post-operative intensity-modulated radiation therapy and non-intensity-modulated radiation therapy patients. Int J Radiat Oncol. 2017;99:E286–E287.
   PubMed Web of Science ®Google Scholar
• Foerster R, Schnetzke L, Bruckner T, et al. Prognostic factors for long-term quality of life after adjuvant radiotherapy in women with endometrial cancer. Strahlenther Onkol. 2016;192:895–904.
   PubMed Web of Science ®Google Scholar
• Rovirosa Á, Cortés·KS, Ascaso·C, et al. Are endometrial cancer radiotherapy results age related? Clin Transl Oncol. 2018;20:1416–1421.
   PubMed Web of Science ®Google Scholar
• Soisson S, Ganz PA, Gaffney D, et al. Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study. Gynecol Oncol. 2018;148:499–506.
   PubMed Web of Science ®Google Scholar
• Heron DE, Gerszten K, Selvaraj RN, et al. Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms. Gynecol Oncol. 2003;91:39–45.
   PubMed Web of Science ®Google Scholar
• Canlorbe G, Bendifallah S, Laas E, et al. Tumor size, an additional prognostic factor to include in low-risk endometrial cancer: results of a french multicenter study. Ann Surg Oncol. 2016;23:171–177.
   PubMed Web of Science ®Google Scholar
• Bendifallah S, Canlorbe G, Collinet P, et al. Just how accurate are the major risk stratification systems for early-stage endometrial cancer? Br J Cancer. 2015;112:793–801.
   PubMed Web of Science ®Google Scholar